Wyeth pharmecuticals is working with cambridge college.
its in phase 2 of fda approval.
its in phase 2 of fda approval.
-
Hello, this board in now turned off and no new posting.
Please REGISTER at Anabolic Steroid Forums, and become a member of our NEW community!
-
Check Out IronMag Labs® KSM-66 Max - Recovery and Anabolic Growth Complex
Myostatin gene
- Thread starter BigAL
- Start date
Tatyana
Registered
Yes but that is not the algae thing, this is recombinant monoclonal antibodies (MYO-029) to myostatin. It will be trialed on people with muscular dystrophies.
As for the other supplement, found this:
1: Int J Sport Nutr Exerc Metab. 2004 Aug;14(4):461-72. Links
Effects of an alleged myostatin-binding supplement and heavy resistance training on serum myostatin, muscle strength and mass, and body composition.
??? Willoughby DS.
Exercise and Biochemical Nutrition Laboratory, Dept of Health, Human Performance, and Recreation, Baylor University, Waco, TX 76798-7313, USA.
This study examined 12 wk of resistance training and cystoseira canariensis supplementation on serum levels of myostatin and follistatin-like related gene (FLRG) and muscle strength and body composition. Twenty-two untrained males were randomly assigned to a placebo (PLC) or myostatin binder (MYO) group in a double-blind fashion. Blood was obtained before and after 6 and 12 wk of training. PLC and MYO trained thrice weekly using 3 sets of 6 to 8 repetitions at 85 % to 90 % 1 repetition maximum. MYO ingested 1200 mg/d of cystoseira canariensis. Data were analyzed with 2-way ANOVA. After training, total body mass, fat-free mass, muscle strength, thigh volume/mass, and serum myostatin and FLRG increased for both groups (P < 0.05); however, there were no differences between groups (P > 0.05). Twelve wk of heavy resistance training and 1200 mg/d of cystoseira canariensis supplementation appears ineffective at inhibiting serum myostatin and increasing muscle strength and mass or decreasing fat mass.
x
x
x
T
sorry that i am going to bust everybody's hope here.
The chance of recreational application of any current in research mysostatin inhibitor is not plausible in at least next 20 years.
First of all, development for novel therapruticals are extremely expensive and slow. To get to a lead compound into market cost an average of 800 mil. This process usually takes about 10-12 years from pre-clinical data to FDA approval. Get a drug into phase 2 clincal trial means nothing because phase 1 and 2 trials are based on small samples. It is the phase 3 clinical trials that makes the difference and take the most of the time (3-4 years). Only 20%-30% of drugs in phase two make it to phase 3.
also, the pharmaceutical company need to recover the 800mil that it spend on developing this drug. So even this drug evetually hits the market, the price would be low, especially if it is humanised antibody. for example, the a dose of anti-cancer humanised antibody "herceptin" costs $25,000. The price of a new pharmaceutical will often remain high until the patent expires which is 14 years.
this means that for those want to use this product, it is going to be a long wait (unless you are filthy rich, in that case 5 years if you are lucky).
On top of that, humanised antibody is just pure nastiness. There are numerous side effects associated with it, hypersensitivity for sure, maybe susceptibility to infections, hpertension, weight loss, suppressed apetite depends on the action of mode of the drug. the study above mention was carried out was in the name of "treating muscular atrophy", not for "increasing muscle mass". Otherwise, such "medically insignificant" study would never have been funded.
so there you go.
The chance of recreational application of any current in research mysostatin inhibitor is not plausible in at least next 20 years.
First of all, development for novel therapruticals are extremely expensive and slow. To get to a lead compound into market cost an average of 800 mil. This process usually takes about 10-12 years from pre-clinical data to FDA approval. Get a drug into phase 2 clincal trial means nothing because phase 1 and 2 trials are based on small samples. It is the phase 3 clinical trials that makes the difference and take the most of the time (3-4 years). Only 20%-30% of drugs in phase two make it to phase 3.
also, the pharmaceutical company need to recover the 800mil that it spend on developing this drug. So even this drug evetually hits the market, the price would be low, especially if it is humanised antibody. for example, the a dose of anti-cancer humanised antibody "herceptin" costs $25,000. The price of a new pharmaceutical will often remain high until the patent expires which is 14 years.
this means that for those want to use this product, it is going to be a long wait (unless you are filthy rich, in that case 5 years if you are lucky).
On top of that, humanised antibody is just pure nastiness. There are numerous side effects associated with it, hypersensitivity for sure, maybe susceptibility to infections, hpertension, weight loss, suppressed apetite depends on the action of mode of the drug. the study above mention was carried out was in the name of "treating muscular atrophy", not for "increasing muscle mass". Otherwise, such "medically insignificant" study would never have been funded.
so there you go.
what a buzzkill
